Hematology

Bluebird Bio plans to submit its biologics license application in the US by mid 2021.

The professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed the benefits of CAR T-cell for patients with follicular lymphoma.

The chief technology and chief executive officer of Mustang Bio discussed the company’s integrated approach to drug development.

Experts discussed their recommendations for second-line treatment options for patients with DLBCL.

A drop in endogenous Factor VIII expression was observed from treatment to 5-year follow-up despite continued demonstration of efficacy.

Encouraging results from the phase 1 BrainChild-01 trial were recently published.

The hematologist/oncologist from the Harold C. Simmons Comprehensive Cancer Center discussed the updated results of the KarMMa trial in relapsed/refractory multiple myeloma.

Manuel Litchman, MD, the president, chief executive officer, and director of Mustang Bio discussed the company’s lead and second program.

The physician from the Dana-Farber Cancer Institute discussed the uptake of novel therapies in heavily pretreated multiple myeloma.

The phase 1b KEYNOTE-B79 trial of CYAD-101 for mCRC is expected to initiate in Q4 2021.

The president, chief executive officer, and director of Mustang Bio discussed the company’s pipeline.

Over 90% participants had an annualized bleeding rate of 0 or a lower bleed rate than baseline after week 4 after treatment.

The hematologist from Mayo Clinic discussed the integration of CAR T-cell therapy into the treatment paradigm for heavily pretreated multiple myeloma.

With advancements happening at unprecedented rates, these are the cell and gene therapy companies and pipelines we’re keeping a close eye on.

The clinical-stage biotech company recently announced the expansion of their phase 1 trial of CYNK-001 in patients with relapsed/refractory acute myeloid leukemia.

Eunice Wang, MD, and Bijal Shah, MD, MS, discussed unmet needs for adult patients with relapsed/refractory ALL and reflect on the current treatment landscape.

Janssen hopes that Vor’s stem cell therapy will allow their bispecific antibody to be better-tolerated.

The hematologist from Moffitt Cancer Center discussed the timing of treatment with chimeric antigen receptor T-cell therapy in patients with acute lymphoblastic leukemia.

Study enrollment has been paused following the development of antibodies in the highest-dosed patient.

Bijal Shah, MD, MS, and Eunice Wang, MD, discuss efficacy results of the ZUMA-3 trial of chimeric antigen receptor (CAR) T-cell therapy for acute lymphocytic leukemia (ALL), and review key safety data.

Eunice Wang, MD, and Bijal Shah, MD, MS, discuss the overall study design and patient population of the ZUMA-3 trial of CAR T-cell therapy in adult patients with R/R ALL.

The physician at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School discussed future directions that ide-cel research may take.

Eunice Wang, MD, and Bijal Shah, MD, MS, discussed the use of MRD status to assess therapeutic response and guide treatment decisions in patients with relapsed/refractory ALL.  

Leo I. Gordon, MD, and others discussed second-line treatment of diffuse large B-cell lymphoma.

Eunice Wang, MD and Bijal Shah, MD, MS, discuss novel agents and emerging therapeutic approaches for the treatment of acute lymphoblastic leukemia.

The director of Mayo Clinic's Lymphoma Program discussed R/R FL and current treatment options.

The director of the Clinical Myeloma Program at NYU Langone Health’s Perlmutter Cancer Center discusses the next steps for CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.

The FDA’s designation follows positive data presented at the 2020 ASH meeting.

The director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center discussed the phase 2 CARTITUDE-2 trial.

The phase 3 ZUMA-7 trial met both its primary and secondary endpoints.